Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice.
Heat-shock proteins (HSPs) act as molecular chaperones binding endogenous antigenic peptides and transporting them to major histocompatibility complexes. HSPs chaperone a broad repertoire of endogenous peptides including tumor antigens. For the immunotherapy of tumors, a strategy using HSPs may be more advantageous than other procedures because the identification of each tumor-specific antigen is not necessary. In this study, the efficacy of immunotherapy against minimal residual leukemia cells using HSP preparations was evaluated. HSP70 and GP96 were purified from syngeneic leukemia cell line A20 and immunized into BALB/c mice during the reconstitution period of the immune system after syngeneic bone marrow transplantation. In this procedure, all mice not immunized were dead within 60 days of A20 inoculation, whereas the survival times of HSP-immunized mice were significantly prolonged. In addition, the depletion of either CD4(+) or CD8(+) T lymphocyte significantly abrogated this efficacy, indicating that both CD4(+) and CD8(+) T lymphocytes were required for tumor cell rejection. Moreover, the vaccination of HSPs elicited a specific response of potent CD8(+) T lymphocytes cytotoxic against A20 in vitro. These observations suggest that immunization of the complex of HSPs and peptides derived from leukemia cells leads to immune responses. These immune responses are sufficient to reject minimal amounts of leukemia cells for relatively immunocompromised mice after syngeneic bone marrow transplantation.
Sato
K
K
Third Department of Internal Medicine, Asahikawa Medical College, Hokkaido, Japan.
Torimoto
Y
Y
Tamura
Y
Y
Shindo
M
M
Shinzaki
H
H
Hirai
K
K
Kohgo
Y
Y
D000818:Animals; D000951:Antigens, Neoplasm / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D018840:HSP70 Heat-Shock Proteins / Q000627:therapeutic use; D006360:Heat-Shock Proteins / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000276:immunology / Q000628:therapy*; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D018365:Neoplasm, Residual; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured; D014611:Vaccination
D000951:Antigens, Neoplasm; D018840:HSP70 Heat-Shock Proteins; D006360:Heat-Shock Proteins; C052646:sarcoma glycoprotein gp96 rejection antigens